Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile ...

Detailed price information for Profound Medical Corp (PRN-T) from The Globe and Mail including charting and trades.
News Medical

Combining MRI and blood tests to avoid unnecessary prostate biopsies

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...
Seeking Alpha

Philips advances minimally invasive therapy procedures in prostate cancer care with FDA 510(k) clearance for image-guided navigation technology

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advancement in image-guided navigation for prostate cancer care with ...
Medscape

MRI-Guided TULSA Shows Faster Recovery Than Robotic Prostatectomy in CAPTAIN Trial

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy ...